Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vital Therapies Enrolls First Subject in VTL-308
SAN DIEGO, May 23, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the first subject was recently enrolled in its phase 3 trial designated
View HTML
Toggle Summary Vital Therapies Announces First Quarter Financial Results
SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the first quarter ended March 31, 2016.
View HTML
Toggle Summary Vital Therapies Announces Upcoming First Quarter Financial Results Conference Call with Webcast and Upcoming Conference Presentation
SAN DIEGO, April 28, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its first quarter 2016 financial results after the market closes on Monday, May
View HTML
Toggle Summary Vital Therapies Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
SAN DIEGO , March 08, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results for the fourth quarter and full year ended December 31, 2015 and
View HTML
Toggle Summary Vital Therapies Announces Upcoming Fourth Quarter and Full Year 2015 Financial Results Conference Call With Webcast
SAN DIEGO, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, will release its fourth quarter and full year 2015 financial results after the market closes on Tuesday,
View HTML
Toggle Summary Vital Therapies Receives FDA Guidance; Announces Upcoming Launch of VTL-308 Phase 3 Trial
SAN DIEGO, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD ® , a cell-based therapy targeting the treatment of liver failure, announced that it has received written responses from the FDA to its Type C meeting request on the
View HTML
Toggle Summary Vital Therapies Announces Late Breaker and Poster Presentations at the Annual Meeting of the American Association for the Study of Liver Disease
SAN DIEGO, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, announced two presentations were given this week at The Liver Meeting, the annual meeting of the American
View HTML
Toggle Summary Vital Therapies Announces Third Quarter 2015 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 5, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today announced results for the third quarter ended September 30, 2015 and provided a corporate update.
View HTML
Toggle Summary Vital Therapies Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares
SAN DIEGO, Oct. 28, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver failure, today announced the closing of its previously announced underwritten public offering of
View HTML
Toggle Summary Vital Therapies Announces Proposed Public Offering of Common Stock
SAN DIEGO, Oct. 22, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver failure, today announced that it intends to offer approximately $30,000,000 of shares of its common stock
View HTML